Skip to main content
Thorax logoLink to Thorax
. 1990 Oct;45(10):740–742. doi: 10.1136/thx.45.10.740

Morning serum cortisol concentrations after 2 mg inhaled beclomethasone dipropionate in normal subjects: effect of a 750 ml spacing device.

M Farrer 1, A J Francis 1, S J Pearce 1
PMCID: PMC462717  PMID: 2247864

Abstract

Large spacing devices have been shown to provide more selective delivery of an inhaled steroid to the lung but the effect on the hypothalamo-pituitary-adrenal suppression associated with high dose inhaled corticosteroids has been little studied. The effect of a large spacing device (Volumatic; 750 ml) on suppression of 0900 h cortisol after 2 mg inhaled beclomethasone dipropionate was therefore investigated in normal, healthy volunteers. Twenty four subjects (12 male, 12 female) took part in a randomised, double blind, placebo controlled cross over study in which a single dose of 2 mg beclomethasone dipropionate was taken at 2300 h on two occasions seven days apart, once from a metered dose inhaler alone and once from a metered dose inhaler attached to a 750 ml spacing device. The 0900 h serum cortisol concentration was the same on the morning before each administration (468 nmol/l, 95% confidence interval (CI) 390-561 nmol/l, day 1 v 479 nmol/l, 95% CI 463-494 nmol/l, day 8). The 0900 h serum cortisol concentration the following morning, however, was lower when 2 mg beclomethasone dipropionate was given by metered dose inhaler alone (182 (95% CI 128-264) nmol/l) than when it was given by a spacing device (363 (95% CI 281-475) nmol/l). These results suggest that a large spacing device attached to a metered dose inhaler may decrease the risk of hypothalamo-pituitary-adrenal suppression by high dose inhaled steroid treatment.

Full text

PDF
740

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ebden P., Jenkins A., Houston G., Davies B. H. Comparison of two high dose corticosteroid aerosol treatments, beclomethasone dipropionate (1500 micrograms/day) and budesonide (1600 micrograms/day), for chronic asthma. Thorax. 1986 Nov;41(11):869–874. doi: 10.1136/thx.41.11.869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Gordon A. C., McDonald C. F., Thomson S. A., Frame M. H., Pottage A., Crompton G. K. Dose of inhaled budesonide required to produce clinical suppression of plasma cortisol. Eur J Respir Dis. 1987 Jul;71(1):10–14. [PubMed] [Google Scholar]
  3. Martin L. E., Tanner R. J., Clark T. J., Cochrane G. M. Absorption and metabolism of orally administered beclomethsone dipropionate. Clin Pharmacol Ther. 1974 Mar;15(3):267–275. doi: 10.1002/cpt1974153267. [DOI] [PubMed] [Google Scholar]
  4. Newman S. P., Morén F., Pavia D., Little F., Clarke S. W. Deposition of pressurized suspension aerosols inhaled through extension devices. Am Rev Respir Dis. 1981 Sep;124(3):317–320. doi: 10.1164/arrd.1981.124.3.317. [DOI] [PubMed] [Google Scholar]
  5. Prahl P., Jensen T. Decreased adreno-cortical suppression utilizing the Nebuhaler for inhalation of steroid aerosols. Clin Allergy. 1987 Sep;17(5):393–398. doi: 10.1111/j.1365-2222.1987.tb02031.x. [DOI] [PubMed] [Google Scholar]
  6. Smith M. J., Hodson M. E. Effects of long term inhaled high dose beclomethasone dipropionate on adrenal function. Thorax. 1983 Sep;38(9):676–681. doi: 10.1136/thx.38.9.676. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES